Nasol Kids, spray 0.125 mcg/dose 10 ml

Antinoconstrictive agent – α-adrenomimetic

ATX code: R01AA04

Pharmacological properties

The drug for symptomatic local treatment of rhinitis. Phenylephrine hydrochloride is an agonist of alpha 1-adrenergic receptors (sympathomimetic) which produces a vasoconstrictor effect at the expense of stimulation of alpha 1-receptors in the nasal mucosa, reduces mucous membrane swelling and tissue hyperemia, congestion in the nasal mucosa and improves nasal airway patency. Restoration of nasopharyngeal airway patency improves the patient’s well-being and reduces the risk of possible complications caused by mucociliary congestion.

Pharmacokinetics

In topical administration, systemic absorption is low.

Indications

Symptomatic treatment: for relief of nasal breathing in colds, flu, hay fever or other allergic upper respiratory diseases accompanied by acute rhinitis or sinusitis.

Active ingredient

Composition

100 ml contain:

the active ingredient :

phenylephrine hydrochloride 0.25 g;

excipients :

benzalkonium chloride 0.018 g,

eucalyptol (cineol) 0.040 g,

glycerol 4,000 g,

macrogol 1500 1,500 g,

Sodium hydrophosphate dihydrate 0.226 g,

Potassium dihydrophosphate 0.101 g,

/p>

dinatrium edetate dihydrate 0.020 g,

Purified water 95.845 g.

How to take, the dosage

Intranasally.

For children aged 6 to 12 years – 2-3 injections into each nasal passage, not more often than every 4 hours.

The duration of treatment without consulting a doctor is not more than 3-5 days.

Interaction

Monoamine oxidase inhibitors (procarbazine, selegiline), tricyclic antidepressants, maprotiline, guanedrel, guanethidine increase the pressor effect and arrhythmogenicity of phenylephrine (with systemic absorption).

Thyroid hormones with systemic absorption of phenylephrine increase (reciprocally) the associated risk of coronary artery disease (especially in coronary atherosclerosis).

Special Instructions

In children systemic absorption of phenylephrine and the associated risk of side effects is higher than in adults.
The duration of use of the drug should not exceed 3 days, if nasal breathing difficulties persist, further use of the drug should be coordinated with the doctor.

Phenylephrine should not be administered to patients within 2 weeks after withdrawal of monoamine oxidase inhibitors because they may increase the severity of adrenergic effects of sympathomimetic agents and increase the risk of cardiovascular side effects.

It is not recommended that more than one person use the same vial to avoid spreading infection. When the vial is squeezed in the upright position, the solution is discharged as a spray; when the vial is squeezed upside down, it is discharged in droplets.

Influence on the ability to drive and use machinery

There are no data on adverse effects of the drug on the ability to drive and other vehicles. However, if symptoms of side effects of the drug are observed, one should refrain from driving vehicles and performing activities requiring concentration or psychomotor reactions.

Synopsis

Contraindications

Cautious in children (under 6 years of age).

Side effects

Local reactions: a burning, tingling or tingling sensation in the nose.

Systemic effects: headache, dizziness, palpitations, arrhythmias, increased blood pressure, sweating, pallor, tremors, sleep disturbances.

Overdose

It may manifest itself as abnormal heart rhythm, increased blood pressure, agitation.

In case of overdose it is necessary to consult a doctor.

Treatment is symptomatic.

Similarities